FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297915396> ?p ?o ?g. }

• W4297915396 endingPage "61" @default.
• W4297915396 startingPage "54" @default.
• W4297915396 abstract "Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are primary myeloid neoplasms in dogs generally considered to have a poor outcome. In this study, we assessed toxicity, efficacy and outcome of concurrent administration of doxorubicin and cytarabine in 11 dogs with myeloid neoplasia. Bone marrow specimens were reviewed by three pathologists and classified as either MDS (n = 2), high grade MDS/early AML (MDS/AML; n = 4) or AML (n = 5). The median number of treatment cycles was 5 (range 1–9) and resolution of cytopenia was reported in 7 of 11 dogs including 2 dogs with MDS, 2 dogs with MDS/AML, and 3 dogs with AML. The median duration of remission in the seven responders was 344 days (range 109–1428) and the median overall survival for all dogs was 369 days. Adverse events consisted of predominantly low-grade gastrointestinal illness and myelosuppression. Three dogs developed grade V toxicity manifesting with heart failure (n = 2) at 369 and 1170 days after diagnosis and acute gastrointestinal side effects (n =1). Despite a limited sample size, these results suggest that a doxorubicin and cytarabine protocol may be considered as a therapeutic option in dogs with myeloid neoplasia. Protocol safety, in particular regarding myocardial toxicity, and efficacy should be further investigated." @default.
• W4297915396 created "2022-10-01" @default.
• W4297915396 creator A5003684895 @default.
• W4297915396 creator A5020086814 @default.
• W4297915396 creator A5026592738 @default.
• W4297915396 creator A5027995244 @default.
• W4297915396 creator A5047857657 @default.
• W4297915396 creator A5065007796 @default.
• W4297915396 creator A5083675587 @default.
• W4297915396 date "2022-10-07" @default.
• W4297915396 modified "2023-10-16" @default.
• W4297915396 title "Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs" @default.
• W4297915396 cites W1985237813 @default.
• W4297915396 cites W1996371366 @default.
• W4297915396 cites W1999436985 @default.
• W4297915396 cites W2010132150 @default.
• W4297915396 cites W2018921017 @default.
• W4297915396 cites W2023864583 @default.
• W4297915396 cites W2033283485 @default.
• W4297915396 cites W2036985800 @default.
• W4297915396 cites W2043471542 @default.
• W4297915396 cites W2045783135 @default.
• W4297915396 cites W2051055882 @default.
• W4297915396 cites W2055697748 @default.
• W4297915396 cites W2065491777 @default.
• W4297915396 cites W2070235992 @default.
• W4297915396 cites W2072405390 @default.
• W4297915396 cites W2075762137 @default.
• W4297915396 cites W2107947031 @default.
• W4297915396 cites W2112926904 @default.
• W4297915396 cites W2120512809 @default.
• W4297915396 cites W2127970013 @default.
• W4297915396 cites W2136586944 @default.
• W4297915396 cites W2142770007 @default.
• W4297915396 cites W2161575410 @default.
• W4297915396 cites W2179942122 @default.
• W4297915396 cites W2315890621 @default.
• W4297915396 cites W2339658711 @default.
• W4297915396 cites W2617064917 @default.
• W4297915396 cites W2761147299 @default.
• W4297915396 cites W2772316273 @default.
• W4297915396 cites W2911764061 @default.
• W4297915396 cites W2991317027 @default.
• W4297915396 cites W3015068689 @default.
• W4297915396 cites W3023308515 @default.
• W4297915396 cites W3047204205 @default.
• W4297915396 cites W3119005160 @default.
• W4297915396 cites W3134703711 @default.
• W4297915396 cites W3186843995 @default.
• W4297915396 cites W4241779124 @default.
• W4297915396 cites W4243795630 @default.
• W4297915396 cites W4244883061 @default.
• W4297915396 doi "https://doi.org/10.1111/vco.12860" @default.
• W4297915396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36153810" @default.
• W4297915396 hasPublicationYear "2022" @default.
• W4297915396 type Work @default.
• W4297915396 citedByCount "0" @default.
• W4297915396 crossrefType "journal-article" @default.
• W4297915396 hasAuthorship W4297915396A5003684895 @default.
• W4297915396 hasAuthorship W4297915396A5020086814 @default.
• W4297915396 hasAuthorship W4297915396A5026592738 @default.
• W4297915396 hasAuthorship W4297915396A5027995244 @default.
• W4297915396 hasAuthorship W4297915396A5047857657 @default.
• W4297915396 hasAuthorship W4297915396A5065007796 @default.
• W4297915396 hasAuthorship W4297915396A5083675587 @default.
• W4297915396 hasConcept C126322002 @default.
• W4297915396 hasConcept C143998085 @default.
• W4297915396 hasConcept C197934379 @default.
• W4297915396 hasConcept C2778041864 @default.
• W4297915396 hasConcept C2778729363 @default.
• W4297915396 hasConcept C2779282312 @default.
• W4297915396 hasConcept C2780007613 @default.
• W4297915396 hasConcept C2780366003 @default.
• W4297915396 hasConcept C2780817109 @default.
• W4297915396 hasConcept C29730261 @default.
• W4297915396 hasConcept C71924100 @default.
• W4297915396 hasConcept C90924648 @default.
• W4297915396 hasConceptScore W4297915396C126322002 @default.
• W4297915396 hasConceptScore W4297915396C143998085 @default.
• W4297915396 hasConceptScore W4297915396C197934379 @default.
• W4297915396 hasConceptScore W4297915396C2778041864 @default.
• W4297915396 hasConceptScore W4297915396C2778729363 @default.
• W4297915396 hasConceptScore W4297915396C2779282312 @default.
• W4297915396 hasConceptScore W4297915396C2780007613 @default.
• W4297915396 hasConceptScore W4297915396C2780366003 @default.
• W4297915396 hasConceptScore W4297915396C2780817109 @default.
• W4297915396 hasConceptScore W4297915396C29730261 @default.
• W4297915396 hasConceptScore W4297915396C71924100 @default.
• W4297915396 hasConceptScore W4297915396C90924648 @default.
• W4297915396 hasIssue "1" @default.
• W4297915396 hasLocation W42979153961 @default.
• W4297915396 hasLocation W42979153962 @default.
• W4297915396 hasOpenAccess W4297915396 @default.
• W4297915396 hasPrimaryLocation W42979153961 @default.
• W4297915396 hasRelatedWork W183872195 @default.
• W4297915396 hasRelatedWork W1984510961 @default.
• W4297915396 hasRelatedWork W2015304356 @default.
• W4297915396 hasRelatedWork W2161768235 @default.

• next